<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01172197</url>
  </required_header>
  <id_info>
    <org_study_id>2008-002136-15</org_study_id>
    <secondary_id>2008-002136-15</secondary_id>
    <secondary_id>2008 AN02</secondary_id>
    <secondary_id>08/S1402/30</secondary_id>
    <secondary_id>24891/0009/001-0001</secondary_id>
    <nct_id>NCT01172197</nct_id>
  </id_info>
  <brief_title>Comparison of Levobupivacaine and Ropivacaine for Femoral Neural Block</brief_title>
  <official_title>A Randomised Single Blind Study Comparing the Molar Median Effective Dose of Levobupivacaine and Molar Median Effective Dose of Ropivacaine When Administered as a Femoral Perineural Infusion for Pain Relief After Total Knee Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Tayside</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NHS Tayside</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The anaesthetic management of patients undergoing total knee replacement is still not
      standardised. Epidural analgesia is common, but is associated with bilateral lower limb motor
      block and limited mobilisation. Spinal anaesthesia with intrathecal morphine provides good
      pain relief, but only for 12 to 16 hours, and is often associated with nausea and vomiting.
      Combined single injection femoral / sciatic blocks give good pain relief, but for a variable
      length of time (between 12 and 24 hours).

      In contrast, continuous femoral perineural infusion of local anaesthetic provides very good
      pain relief for several days. Pain relief is maintained by a constant infusion of local
      anaesthetic using an elastomeric ball. The investigators overriding aim is to develop a local
      anaesthetic regimen which offers complete pain relief for at least 48 hours, yet allows full
      mobilisation within 24 hours Given that ropivacaine may offer a more advantageous
      pharmacological profile (less lipid solubility) compared to levobupivacaine, the
      investigators feel it is pertinent to investigate the capacity of ropivacaine to prevent pain
      relief after surgery. Thus, the investigators aim in this study is to compare the median
      effective dose of levobupivacaine with the of ropivacaine for preventive pain relief after
      total knee replacement. Further, calculation of the equipotent median effective dose's of
      each local anaesthetic allied to objective measurement of quadriceps motor block using an
      electromyogram will allow us to determine the sensory - motor split of each local
      anaesthetic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective The primary aim of this study is to measure the molar of levobupivacaine
      and the molar median effective dose of ropivacaine when administered as a femoral perineural
      infusion to prevent pain 30 hours after total knee replacement Secondary objectives

      To assess the:

      Degree of postoperative pain, need for rescue analgesia,side effect profile of both groups,
      self-efficacy, expectancy, quality of life / health economics Type of study: Prospective
      single blind randomised controlled trial Planned number of subjects: 48 Study duration: 24
      months Randomisation procedures Following informed consent, participants will be randomised
      into two groups. All preparations for study will be coded so that participants have an equal
      chance of receiving one of the two local anesthetics. Randomisation will be carried out by
      computer program, and codes kept in pharmacy in a sealed envelope.

      Protocol for patient management Preoperative - Anaesthetic room Antibiotics: augmentin 1.2
      grams Sedation with Target Controlled Infusion of propofol at plasma level of 0.5 micrograms
      per millilitre (μg.ml-1) Spinal anaesthesia with 3.2 ml hypobaric &quot;plain&quot; bupivacaine 0.5%
      and intrathecal morphine 0.1 mg All regional nerve blocks performed under ultrasound control
      Femoral block: 15 ml 0.3% levobupivacaine or ropivacaineFemoral perineural catheter inserted
      by Anaesthetist 5cm in a cranial direction Sciatic block: single injection 12 ml 0.5%
      levobupivacaine or ropivacaine Obturator block: single injection 6 ml 0.5% levobupivacaine or
      ropivacaine

      Postoperative 8 hour anaesthetic observation

      Determine median effective dose of levobupivacaine and ropivacaine for anaesthesia 8 hours
      after insertion of spinal needle, resolution of spinal anaesthesia confirmed and verbal
      rating pain score of knee bending recorded. Clinical measurement and subsequent patient
      dosing is as follows:

        1. &quot;Anaesthetic success&quot;: verbal rating pain score = 0: Next patient receives 10 microMolar
           (μM) less of levobupivacaine or 10μM ropivacaine.

        2. &quot;Anaesthetic failure&quot;: verbal rating pain score ≥ 1. Resolved by rescue analgesia of
           15ml, 150μM levobupivacaine (5.8ml, 0.75%) or 15ml, 150μM ropivacaine (6.2ml,
           0.75%).Next patient receives 10μM more of levobupivacaine or 10μM ropivacaine.

        3. Technical failure: verbal rating pain score ≥ 1 Not resolved by rescue analgesia of
           15ml, 150μM levobupivacaine (5.8ml, 0.75%) or 15ml, 150μM ropivacaine (6.2ml, 0.75%.Next
           patient receives same mass levobupivacaine or ropivacaine.

      After the 8 hour assessment, all patients (excluding technical failures but including
      &quot;anaesthetic failures&quot;) will start a femoral perineural infusion with levobupivacaine or
      ropivacaine at a rate of 10ml h-1 and concentration of 1(microMolar per millilitre) μM.ml-1
      (400μM in 400ml elastomeric ball) for 48 hours.Patients classed as &quot;technical failure&quot; will
      have a femoral perineural catheter reinserted.

      Postoperative 30 hour (±2hour) anaesthetic observation

      The postoperative 30 hour anaesthetic observation will only be performed on the &quot;anaesthetic
      successes&quot; from the 8 hour observation. The median effective dose of levobupivacaine and
      ropivacaine for analgesia will be determined by choosing an end point of verbal rating pain
      score 0 at 30h after the start of spinal anaesthesia. Patients will divide into three groups:

        1. &quot;Successful pain relief&quot; verbal rating pain score = 0 Next patient receives 10μM less of
           levobupivacaine or 10μM ropivacaine.

        2. &quot;Unsuccessful pain relief&quot; verbal rating pain score ≥ 1 resolved by rescue analgesia of
           15ml, 50μM levobupivacaine (5.8ml, 0.25% + saline) or 15ml, 50μM ropivacaine (7.7ml,
           0.20% + saline).Next patient receives 10μM more of levobupivacaine or 10μM ropivacaine.

        3. Technical failure: verbal rating pain score ≥ 1. Not resolved by rescue analgesia of
           15ml, 50μM levobupivacaine (5.8ml, 0.25% + saline) or ml, 50μM ropivacaine (7.7ml, 0.20%
           + saline).

      Rescue analgesia Rescue will be standardised: 15ml, 50μM levobupivacaine (5.8ml, 0.25% +
      saline) or 15ml, 50μM ropivacaine (7.7ml, 0.20% + saline). The number of rescue
      administrations will be counted.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated prior to its planned completion as anticipated by the protocol).
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>30 hours</time_frame>
    <description>Number achieving pain on movement of knee measured as 0 on a verbal pain rating scale at 30h after start of perineural infusion</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Pain</condition>
  <condition>Arthroplasty, Replacement, Knee</condition>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Local anaesthetic bolus and infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Local anaesthetic bolus and infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine</intervention_name>
    <description>Femoral bolus 150μM followed by femoral infusion 400μM</description>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>Chirocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Bolus and infusion</description>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients &gt;18 years of age and non pregnant presenting for elective knee
             replacement

        Exclusion Criteria:

          -  Signs of cardiac failure (3rd heart sound, lung crepitations)

          -  Type I and type II diabetes

          -  Abnormal cardiac arrhythmias

          -  Hypovolaemia

          -  Presence of seizures,

          -  Dementia,

          -  Depression

          -  Encephalopathy,

          -  Terminal illness with a life expectancy &lt; 3 months

          -  Age &lt; 18 years

          -  Pregnant

          -  Coagulopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graeme A McLeod, MD FRCA</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHS Tayside</affiliation>
  </overall_official>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2010</study_first_submitted>
  <study_first_submitted_qc>July 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2010</study_first_posted>
  <results_first_submitted>April 9, 2018</results_first_submitted>
  <results_first_submitted_qc>April 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 9, 2018</results_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>local anesthetic</keyword>
  <keyword>levobupivacaine</keyword>
  <keyword>ropivacaine</keyword>
  <keyword>femoral perineural block</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited on ward 24h before procedure. Patient information sheet sent to patients 3 weeks before operation</recruitment_details>
      <pre_assignment_details>Nil to report</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ropivacaine</title>
          <description>Local anaesthetic bolus and infusion
Levobupivacaine: Femoral bolus 150μM followed by femoral infusion 400μM</description>
        </group>
        <group group_id="P2">
          <title>Levobupivacaine</title>
          <description>Local anaesthetic bolus and infusion
Ropivacaine: Bolus and infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ropivacaine</title>
          <description>Local anaesthetic bolus and infusion
Levobupivacaine: Femoral bolus 150μM followed by femoral infusion 400μM</description>
        </group>
        <group group_id="B2">
          <title>Levobupivacaine</title>
          <description>Local anaesthetic bolus and infusion
Ropivacaine: Femoral bolus 150μM followed by femoral infusion 400μM</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="53" upper_limit="70"/>
                    <measurement group_id="B2" value="64" lower_limit="56" upper_limit="72"/>
                    <measurement group_id="B3" value="62" lower_limit="53" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain</title>
        <description>Number achieving pain on movement of knee measured as 0 on a verbal pain rating scale at 30h after start of perineural infusion</description>
        <time_frame>30 hours</time_frame>
        <population>Knee replacement. All obtained pain relief defined as pain score = 0 on a verbal pain rating scale</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine</title>
            <description>Local anaesthetic bolus and infusion
Levobupivacaine: Femoral bolus 150μM followed by femoral infusion 400μM</description>
          </group>
          <group group_id="O2">
            <title>Levobupivacaine</title>
            <description>Local anaesthetic bolus and infusion
Ropivacaine: Bolus and infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Number achieving pain on movement of knee measured as 0 on a verbal pain rating scale at 30h after start of perineural infusion</description>
          <population>Knee replacement. All obtained pain relief defined as pain score = 0 on a verbal pain rating scale</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30h</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ropivacaine</title>
          <description>Local anaesthetic bolus and infusion
Levobupivacaine: Femoral bolus 150μM followed by femoral infusion 400μM</description>
        </group>
        <group group_id="E2">
          <title>Levobupivacaine</title>
          <description>Local anaesthetic bolus and infusion
Ropivacaine: Bolus and infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr G McLeod</name_or_title>
      <organization>NHS Tayside</organization>
      <phone>+44 1382 7974440848</phone>
      <email>g.a.mcleod@dundee.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

